FDA Approves TherapeuticsMD's Low Dose Bijuva

FDA Approves TherapeuticsMD's Low Dose Bijuva

TherapeuticsMD Inc TXMD is trading sharply higher after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause.

Posted In: Briefswhy it's movingBiotechLong IdeasNewsPenny StocksHealth CareFDAMoversTrading IdeasGeneral